quazepam (doral) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Quazepam is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Quazepam interact preferentially with the benzodiazepine-1 (BZ1) receptors. Most common adverse reactions (>1%): drowsiness, headache, fatigue, dizziness, dry mouth, dyspepsia. Downward of CAN depressant dose adjustment may be necessary due to additive effects.   NCATS

Chemistry

  • SMILES: FC1=CC=CC=C1C2=NCC(=S)N(CC(F)(F)F)C3=CC=C(Cl)C=C23
  • InChIKey: IKMPWMZBZSAONZ-UHFFFAOYSA-N
  • Mol. Mass: 386.794
  • ALogP: 5.03
  • ChEMBL Molecule:
    quazepam  
More Chemistry

Pharmacology

Alternative names

7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2h-1,4-benzodiazepine-2-thione | doral | prosedar | quazepam | quazepamum | quazium | quiedorm | sch 16134 | sch-16134

Organizations (2)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Sleep Initiation and Maintenance Disorders (approved 1985)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue